Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basophil activation after systemic allergic reaction to taspoglutide
2011-001935-21Phase 3Completed
- Sponsor
- Ipsen
- Start
- Dec 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of taspoglutide in type 2 diabetes mellitus (T2DM), sponsored by Ipsen. Primary endpoint: Basophil activation test result. Started Dec 2011; status: completed.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001935-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001935-21.